

## **Pediatric Respiratory Disease Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023-28)**

Market Report | 2023-01-23 | 115 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The pediatric respiratory disease therapeutics market is expected to register a CAGR of 5.6% over the forecast period.

The pandemic significantly impacted the pediatric respiratory disease therapeutics market as the demand for pediatric respiratory disease therapeutics products increased owing to the increased risk of respiratory illness. For instance, as per a study published by the NCBI in September 2022, low-field magnetic MRI showed persistent pulmonary dysfunction in both children and adolescents who recovered from COVID-19 and with long COVID. Similarly, per the study published by the IJP in November 2021, the pandemic has brought significant challenges to childcare worldwide. Respiratory disease therapeutics such as anti-inflammatory drugs, bronchodilators, and combination drugs are generally used for the treatment of various respiratory diseases. Thus, the increasing incidence of respiratory diseases among pediatrics and continuous treatment during the pandemic helped the market to maintain considerable growth. With the emergence of the new strain, the market is expected to move upward over the forecast period.

The increasing prevalence of chronic respiratory diseases and increasing research and development in drug discovery for respiratory diseases are the major drivers for the market. For instance, as per the report published by the WHO in October 2022, an estimated 10.6 million people suffered from tuberculosis (TB) in 2021 globally of which 1.2 million were children. The report also stated that TB is prevalent in all countries and age groups. In addition, the burden of asthma and allergic diseases continues to increase among pediatrics. Moreover, every year pediatric respiratory infections impose a significant burden on the global healthcare system in terms of manpower and resource utilization.

Furthermore, as per the October 2021 CDC report, there were more than 317 cases of tuberculosis disease among children aged 14 years or younger in the United States, accounting for 4.0% of all people reported with tuberculosis nationally in 2021.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott-international.com](mailto:support@scott-international.com)

[www.scott-international.com](http://www.scott-international.com)

According to UNICEF data published in August 2022, there were more than 1,400 cases of pneumonia per 100,000 children, or 1 case in 71 children each year, globally, with the highest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children).

The increasing research and development in drug discovery is also another driving factor for the market. For instance, as per the journal published by the Frontiers Organization in October 2021, research is being conducted to identify prognostic respiratory disorder/disease progression-specific biomarkers that can predict disease course in children and to develop scoring and risk stratification systems. Similarly, in September 2021, Children's National Hospital received USD 2.13 million in awards from the National Institutes of Health's (NIH) National Heart, Lung and Blood Institute to accelerate research work and develop new diagnostic tools and innovative precision medicine related to treatments for kids with down syndrome experiencing respiratory viruses. It is expected that such advancements may create new opportunities for the market and may encourage new players to enter the market.

#### Pediatric Respiratory Disease Therapeutics Market Trends

##### The Asthma Segment is Expected to Witness Considerable Growth Over the Forecast Period

Asthma is the most common chronic respiratory disease affecting children globally. Asthma is a chronic (long-term) condition that affects the airways in the lungs. The airways of asthma patients can sometimes become inflamed and narrow. This makes it difficult for air to flow out of the airways when exhaling. Asthma is a major non-communicable disease (NCD) and can also affect adults.

The increasing number of pediatric asthma cases is one of the major drivers for the segment's growth. For instance, per the journal published by the ERJ open research in August 2022, a study based on the ISAAC questionnaire reported a prevalence rate of bronchial asthma of 13.1% in children aged 11 to 16 across the globe. Similarly, per the report published by the CDC in May 2022, 1 in 12, about 6.0 million children in the United States aged 0-17 years, suffer from asthma every year. Such instances indicate that the demand for asthma drugs and therapeutics is anticipated to increase, propelling segment growth.

The new product launch and approvals of drugs for treating asthma in children are also anticipated to propel the segment growth. For instance, in October 2021, the United States Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance treatment for patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Similarly, in December 2021, AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) has been approved in the United States for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

##### North America is Expected to Witness Significant Growth Over the Forecast Period

North America is expected to dominate the overall pediatric respiratory disease therapeutics market over the forecast period. The factors driving the market are increasing cases of pediatric respiratory diseases, increasing research work, and continuous product launches and approvals. According to a report published by Asthma Canada in June 2021, more than 850,000 children under the age of 14 have asthma, making it the most common chronic disease among children and the leading cause of both school absenteeism and hospitalization in Canada. Similarly, as per the journal published by the CMAJ Group in May 2021, asthma is the most common chronic disease in children, with a prevalence of 15.0% to 25.0% in Canada.

Key product launches, high concentration of market players or manufacturer's presence, acquisition and partnerships among major players, and increasing cases of respiratory diseases and research works and clinical trials in the United States are some of the factors driving the growth of the pediatric respiratory disease therapeutics market in the country. For instance, in April 2021,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Sanofi's Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in the Phase 3 trial.

## Pediatric Respiratory Disease Therapeutics Market Competitor Analysis

The pediatric respiratory disease therapeutics market is moderately competitive due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known including Novartis AG, Bayer AG, GlaxoSmithKline plc, Merck & Co, Boehringer Ingelheim GmbH, AstraZeneca plc among others.

Additional Benefits:

The market estimate (ME) sheet in Excel format  
3 months of analyst support

### **Table of Contents:**

#### 1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

#### 2 RESEARCH METHODOLOGY

#### 3 EXECUTIVE SUMMARY

#### 4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
  - 4.2.1 Increasing Prevalence of Chronic Respiratory Diseases
  - 4.2.2 Increasing Research and Development in Drug Discovery for Respiratory Diseases
- 4.3 Market Restraints
  - 4.3.1 Stringent Regulations for Drug Approval
- 4.4 Porter's Five Forces Analysis
  - 4.4.1 Threat of New Entrants
  - 4.4.2 Bargaining Power of Buyers/Consumers
  - 4.4.3 Bargaining Power of Suppliers
  - 4.4.4 Threat of Substitute Products
  - 4.4.5 Intensity of Competitive Rivalry

#### 5 MARKET SEGMENTATION (Market Size by Value - USD Million)

- 5.1 By Drug Class
  - 5.1.1 Anti-Inflammatory Drugs
  - 5.1.2 Bronchodilators
  - 5.1.3 Combination Drugs
  - 5.1.4 Corticosteroid
  - 5.1.5 Monoclonal Antibodies
  - 5.1.6 Other Drug Classes
- 5.2 By Disease
  - 5.2.1 Asthma

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.2.2 Cystic Fibrosis
- 5.2.3 Bronchiolitis
- 5.2.4 Pneumonia
- 5.2.5 Tuberculosis
- 5.2.6 Other Diseases
- 5.3 Geography
  - 5.3.1 North America
    - 5.3.1.1 United States
    - 5.3.1.2 Canada
    - 5.3.1.3 Mexico
  - 5.3.2 Europe
    - 5.3.2.1 Germany
    - 5.3.2.2 United Kingdom
    - 5.3.2.3 France
    - 5.3.2.4 Italy
    - 5.3.2.5 Spain
    - 5.3.2.6 Rest of Europe
  - 5.3.3 Asia-Pacific
    - 5.3.3.1 China
    - 5.3.3.2 Japan
    - 5.3.3.3 India
    - 5.3.3.4 Australia
    - 5.3.3.5 South Korea
    - 5.3.3.6 Rest of Asia-Pacific
  - 5.3.4 Middle East
    - 5.3.4.1 GCC
    - 5.3.4.2 South Africa
    - 5.3.4.3 Rest of Middle East
  - 5.3.5 South America
    - 5.3.5.1 Brazil
    - 5.3.5.2 Argentina
    - 5.3.5.3 Rest of South America

## 6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
  - 6.1.1 F. Hoffmann-La Roche AG (Genentech, Inc.)
  - 6.1.2 Novartis AG
  - 6.1.3 Bayer AG
  - 6.1.4 GlaxoSmithKline plc
  - 6.1.5 Merck & Co
  - 6.1.6 Boehringer Ingelheim GmbH
  - 6.1.7 Regeneron Pharmaceuticals
  - 6.1.8 AstraZeneca plc
  - 6.1.9 Vertex Pharmaceuticals Incorporated
  - 6.1.10 Johnson & Johnson

## 7 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Pediatric Respiratory Disease Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023-28)**

Market Report | 2023-01-23 | 115 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-27"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

